|
Research Update: MediGene AG 08. November 2011  Biotechnology MediGene should report third quarter 2011 results on 11 November. The group seeks to develop blockbuster compounds, but success to date ... ...Subscribe to VISCARDI Research... |
|
Research Update: MediGene AG 10. August 2010 Still waiting for an Endo-TAG deal MediGene reported first half 2010 sales of €26m up 26% compared to €20m last year. EBITDA losses fell by 20% to €5.4m. Net losses more than ... ...VISCARDI Research bestellen... |
|
Research Update: MediGene AG 26. Mai 2010 Still burning cash too quickly. MediGene’s first quarter 2010 results saw revenues up by 3% to €12m. EBITDA losses though increased to €2.4m against €1.9m. Net losses increased by ... ...VISCARDI Research bestellen... |
|
Research Update: MediGene AG 14. Juli 2009 Waiting on EndoTAG-1 MediGene reports first half results on 7 August. Sales should have continued to grow sharply with falling losses. However, net cash is also falling fast. The group had net cash of ... ...VISCARDI Research bestellen... |
|
Research Update: MediGene AG 01. April 2009 Sufficient cash and facilities for over two years MediGene reported 2008 results in line with our October expectations. Sales rose by 66% to €39.6m (our est €39.0m) and the EBITDA loss was reduced by ... ...VISCARDI Research bestellen... |
|
Research update: MediGene AG 09. Oktober 2008 Better focus improves value
|
|
Research update: MediGene AG 25. April 2008 Recommended approval of Oracea MediGene reported further positive news with the recommended granting of approval by the European Regulatory Authority for the sale of Oracea. The formal approval by the European Commission is expected in the next weeks. Oracea is for the treatment of the skin disease rosacea and could have ... ...Subscribe to VISCARDI Research... |
|
Research update: MediGene AG 19. März 2008 Positive EndoTAG-1 clinical trial results MediGene's cancer treatment compound EndoTAG-1 has shown highly positive phase two clinical trial results. This suggests the group could accelerate further trials, possibly in a partnership. MediGene already has two approved drugs on the market, Eligard and Veregen. The group has several other compounds under development for the treatment... ...Subscribe to VISCARDI Research... |
|
Research Update: MediGene 03. November 2006 US regulatory approval for Polyphenon E MediGene's genital warts treatment Polyphenon E has received FDA approval for sale in the US. MediGene will now receive in this quarter an EUR 11m milestone payment from its US distributor. Polyphenon E is expected to on sale ... ...Subscribe to VISCARDI Research... |
|
Research update: MediGene 03. Mai 2006 Profitable first quarter 2006 figures First quarter 2006 sales rose by 74% to €6.6m. With several launches of Eligard in European markets the cost of goods sold increased to €1.2m from just €0.4m. Royalty payments to QLT also increased for ... ...Subscribe to VISCARDI Research... |
|
Research note: MediGene 02. März 2006 Sales up 50% in 2005, same growth in 2006e MediGene’s sales in 2005 jumped 50% to €19.7m. A similar growth rate is expected in 2006. EBIT losses in 2005 were cut by 22% to €11.5m, but with ... ...Subscribe to VISCARDI Research... |
|
Research Medigene AG 01. Juli 2005 Medigene AG VISCARDI Securities GmbH just released a research note of Medigene AG ...Subscribe to VISCARDI Research... |